Cysteine Hydrochloride · CYSTEINE HYDROCHLORIDE 10 mg/mL · Injection, Solution · Intravenous · Exela Pharma Sciences, LLC
NDC 51754-1007-03 · 100 mL in 1 CARTON · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. One of its named manufacturing plants, Exela Pharma Sciences, LLC., failed FDA inspectionwithin the last two years — the agency’s most serious outcome.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 11510942 | Jan 15, 2039 |
| patent | 11969439 | Jan 15, 2039 |
| patent | 10478453 | Jan 15, 2039 |
| patent | 10583155 | Jan 15, 2039 |
| patent | 10653719 | Jan 15, 2039 |
| patent | 10918662 | Jan 15, 2039 |
| patent | 10905713 | Jan 15, 2039 |
| patent | 10905714 | Jan 15, 2039 |
| patent | 11684636 | Jan 15, 2039 |
| patent | 10933089 | Jan 15, 2039 |
| patent | 11826383 | Jan 15, 2039 |
| patent | 11679125 | Jan 15, 2039 |
No FDA shortage reports for this drug or its presentations.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Exela Pharma Sciences, LLC | CYSTEINE HYDROCHLORIDE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Exela Pharma Sciences, LLC | CYSTEINE HYDROCHLORIDE 50 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Elcys — NDC 51754-1007-03," retrieved September 3, 2026, https://drugdashboards.com/drug/51754100703.
Free to cite with attribution — see how the data is put together.